Add to a list

Suspension of trading

Rayont Inc. Stock

RAYT

US75508M1009

Biotechnology & Medical Research

OTC Markets Traded

Delayed OTC Markets 15:16:38 2024-11-15 EST			5-day change	1st Jan Change
0.000001 ^USD	-100.00%		-.--%	-

23-05-15	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-02-24	Rayont Inc. Announces Board Appointments	CI

Rayont Inc. operates in the personalized natural healthcare sector in United States and Australia. The Company uses scientific tools, such as deoxyribonucleic acid (DNA), microbiome, iridology and other tests to diagnose and personalize the prescription of natural complementary medicine products, services and treatments to its patients in the markets the Company operate. The Company produces a range of products, including proteins, green blends, sports nutrition, weight management and maintenance, and health and wellness products. The Company's subsidiaries include Rayont (Malaysia) Sdn Bhd, Rayont International (L) Limited, Rayont (Australia) Pty Ltd and Prema Life (USA) Inc.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
RAYT Stock

As early as today, start finding the best investment opportunities!

Market Cap	4.47M 3.85M 3.61M 3.3M 6.21M 427M 6.23M 42.83M 16.71M 216M 16.78M 16.41M 715M	P/E 2021	293x	P/E 2022	186x
Enterprise Value	12.25M 10.55M 9.9M 9.03M 17.02M 1.17B 17.07M 117M 45.81M 591M 45.99M 44.99M 1.96B	EV / Sales 2021	47.8x	EV / Sales 2022	18.8x
Free-Float	48.18%	Yield 2021 *	-	Yield 2022	-

23-05-15	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	CI
23-02-24	Rayont Inc. Announces Board Appointments	CI
23-02-14	Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022	CI
23-01-17	Rayont Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022	CI
22-12-29	Rayont Inc. Reports Earnings Results for the Full Year Ended June 30, 2022	CI
22-12-28	Rayont Inc. Auditor Raises 'Going Concern' Doubt	CI
22-05-20	Rayont Inc. Appoints Ilenna Copley as Chief Operating Officer	CI
22-05-17	Rayont Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2022	CI
22-04-25	Rayont Inc. Announces Management Changes	CI
22-04-22	Rayont Inc. Announces Board Resignations	CI
22-03-01	Rayont Inc. Announces Management Changes	CI
22-03-01	Rayont Inc. Announces Executive Changes	CI
22-02-24	Rayont Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2021	CI

23-06-23	Rayont : Non-Reliance on Previously Issued Financial Report - Form 8-K	PU
23-06-23	RAYONT INC. : Non-Reliance on Previous Financials, Audits or Interim Review, Financial Statements and Exhibits (form 8-K)	AQ
23-05-05	RAYONT INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
23-03-31	RAYONT INC. : Financial Statements and Exhibits (form 8-K)	AQ
23-02-24	RAYONT INC. : Change in Directors or Principal Officers (form 8-K)	AQ

3 years	0		0.25
5 years	0		2.75
10 years	0		10.4

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
RAYONT INC.	-100.00%	-.--%	-	-	45
LONZA GROUP AG	-0.81%	-1.50%	+1.40%	+18.43%	50.47B
REVOLUTION MEDICINES, INC.	-2.20%	-3.90%	+414.36%	+498.54%	44.56B
IQVIA HOLDINGS INC.	-1.23%	-0.56%	+40.83%	+16.23%	43.08B
BEONE MEDICINES AG	-3.08%	-4.46%	+7.04%	+71.24%	41.7B
CELLTRION, INC.	-0.31%	-0.83%	+19.47%	+48.24%	33.21B
MEDPACE HOLDINGS, INC.	-1.17%	-4.11%	+25.60%	+119.98%	16.77B
ASCENDIS PHARMA A/S	+6.35%	+4.25%	-	-	16.28B
EUROFINS SCIENTIFIC SE	-0.61%	-1.80%	+10.71%	+26.57%	14.58B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.20%	-3.63%	+78.45%	+39.13%	13.92B
Average	-10.42%	-1.25%	+74.73%	+104.79%	27.46B
Weighted average by Cap.	-0.99%	-1.21%	+88.70%	+121.42%

Rayont Inc. Stock

Stocks

RAYT

US75508M1009

Biotechnology & Medical Research

Valuation : Rayont Inc.

Latest news : Rayont Inc.

Press Releases : Rayont Inc.

Quotes and Performance

Price Extremes

Other Biotechnology & Medical Research

Financials

Company Profile

	2021	2022
Net sales	2.97M 2.56M 2.4M 2.19M 4.13M 284M 4.14M 28.46M 11.11M 143M 11.15M 10.91M 475M	2.84M 2.45M 2.29M 2.09M 3.94M 271M 3.96M 27.22M 10.62M 137M 10.66M 10.43M 454M
Net income	384K 331K 310K 283K 533K 36.69M 535K 3.68M 1.44M 18.52M 1.44M 1.41M 61.41M	245K 211K 198K 181K 340K 23.4M 341K 2.35M 916K 11.81M 919K 899K 39.17M
Net Debt	2.4M 2.07M 1.94M 1.77M 3.34M 230M 3.35M 23.05M 8.99M 116M 9.03M 8.83M 385M	7.78M 6.7M 6.29M 5.74M 10.81M 744M 10.84M 74.57M 29.1M 375M 29.21M 28.57M 1.24B